These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 33852477)

  • 1. Clinical Application of Sacubitril/Valsartan in Heart Failure.
    Liu X; Zhong L
    Am J Ther; 2021 Apr; 28(4):e511-e513. PubMed ID: 33852477
    [No Abstract]   [Full Text] [Related]  

  • 2. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ESC Guidelines on heart failure, sacubitril-valsartan in resistant hypertension, and new therapeutic targets in myocardial hypertrophy.
    Crea F
    Eur Heart J; 2021 Sep; 42(36):3581-3585. PubMed ID: 34549264
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical Application of Sacubitril/Valsartan in Heart Failure: Erratum.
    Am J Ther; 2022 Nov-Dec 01; 29(6):e788. PubMed ID: 36608068
    [No Abstract]   [Full Text] [Related]  

  • 5. The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond.
    Kario K
    Curr Cardiol Rep; 2018 Jan; 20(1):5. PubMed ID: 29374807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Making the Case for an Expanded Indication for Sacubitril/Valsartan in Heart Failure.
    Solomon SD; McMURRAY JJV
    J Card Fail; 2021 Jun; 27(6):693-695. PubMed ID: 33872760
    [No Abstract]   [Full Text] [Related]  

  • 7. The PARAGON Heart Failure trial - ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction.
    Kjeldsen SE; Narkiewicz K; Burnier M; Oparil S
    Blood Press; 2019 Aug; 28(4):215-216. PubMed ID: 31184508
    [No Abstract]   [Full Text] [Related]  

  • 8. Sacubitril/Valsartan: potential treatment for paediatric heart failure.
    Das BB; Scholl F; Vandale B; Chrisant M
    Cardiol Young; 2018 Sep; 28(9):1077-1081. PubMed ID: 29979147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No Improved Patient-Oriented Outcomes With Sacubitril/Valsartan in Adults With Heart Failure and Preserved Ejection Fraction.
    Slawson DC
    Am Fam Physician; 2022 Jun; 105(6):Online. PubMed ID: 35704816
    [No Abstract]   [Full Text] [Related]  

  • 11. Sacubitril/Valsartan in Advanced Heart Failure: Shattering the Paradigm to Focus on Real LIFE.
    Samsky MD; Sen S
    JACC Heart Fail; 2022 Jul; 10(7):457-458. PubMed ID: 35772854
    [No Abstract]   [Full Text] [Related]  

  • 12. Sacubitril-Valsartan in Heart Failure: The Hard Sell of Spending More to Save Later.
    Samson R; Le Jemtel TH
    Am J Cardiol; 2023 Sep; 202():237-238. PubMed ID: 37495439
    [No Abstract]   [Full Text] [Related]  

  • 13. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
    Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
    Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin Receptor Neprilysin Inhibition Across Ejection Fraction and Acuity Spectra in Heart Failure.
    Myhre PL; Lam CSP
    JACC Heart Fail; 2024 Mar; 12(3):583-587. PubMed ID: 38276934
    [No Abstract]   [Full Text] [Related]  

  • 15. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
    Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
    N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sacubitril/valsartan adherence… because the best is sometimes difficult to replace the good.
    Álvarez-García J
    Eur J Heart Fail; 2022 Sep; 24(9):1516-1518. PubMed ID: 35869745
    [No Abstract]   [Full Text] [Related]  

  • 17. Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck.
    Ansara AJ; Kolanczyk DM; Koehler JM
    J Clin Pharm Ther; 2016 Apr; 41(2):119-27. PubMed ID: 26992459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Sacubitril/Valsartan-driven Benefit on Exercise Capacity in Heart Failure With Reduced Ejection Fraction: A Pilot Study.
    Palau P; Mollar A; Domínguez E; Sanchis J; Bayés-Genís A; Núñez J
    Rev Esp Cardiol (Engl Ed); 2019 Feb; 72(2):167-169. PubMed ID: 29373254
    [No Abstract]   [Full Text] [Related]  

  • 19. Mortality and Heart Failure Risk Reductions in Patients Treated With Sacubitril-Valsartan in Clinical Trials.
    Cordero A; Nuñez J; Bertomeu-González V; Fácila L; Quintanilla MA; Rodríguez-Mañero M; Escribano D; Valle A; de la Espriella R; Torres-Llergo J; Bayés-Genís A; González-Juanatey JR
    Am J Ther; 2022 Sep-Oct 01; 29(5):e572-e575. PubMed ID: 36074989
    [No Abstract]   [Full Text] [Related]  

  • 20. Sacubitril/valsartan: Where mechanism meets evidence-based medicine.
    Rivas García S; Álvarez-García J
    Eur J Heart Fail; 2024 Jan; 26(1):127-129. PubMed ID: 38037688
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.